Hormonal therapy in advenced stage prostate cancer
Küçük Resim Yok
Tarih
2015
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Kare Publ
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Prostat cancer is the most common type of cancer in men. At the time of diagnosis, only 5% of prostat cancer patients have the disease in advanced stage. While the 5 year overall survival rate of the patients with locoregional disease is close to 100%, this ratio in patients with advanced disease decreases to 28%. Prostat cancer cells depend on androgens for development, proliferation and physiological function. The purpose of the standard hormone therapy is to keep testesteron levels in castrate levels. Androgen deprivation therapy (ADT) is the standard treatment approach in prostat cancer patients with advanced stage. Although this treatment possesses many clinical benefits, it has also side effects affecting many systems in the body. This article evaluated the types and mechanisms of action of ADT, the management of this treatment's side effects, and the controversial situations commonly encountered in daily oncology practice in the light of current literature.
Açıklama
Anahtar Kelimeler
Androgen Deprivation Therapy, Prostate Cancer, Androgen-Deprivation Therapy, Randomized-Trials, Bilateral Orchiectomy, European Organization, Cyproterone-Acetate, Goserelin Acetate, American-Society, Open-Label, Phase-Iii, Follow-Up
Kaynak
Turk Onkoloji Dergisi-Turkish Journal Of Oncology
WoS Q Değeri
N/A
Scopus Q Değeri
Q4
Cilt
30
Sayı
1
